Use of Oral Tofacitinib in the Treatment of Pediatric Vitiligo: A Case Series
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Olamiju B, Craiglow B
. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child. Pediatr Dermatol. 2020; 37(4):754-755.
DOI: 10.1111/pde.14159.
View
2.
Vu M, Heyes C, Robertson S, Varigos G, Ross G
. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol. 2017; 42(8):942-944.
DOI: 10.1111/ced.13290.
View
3.
Liu L, Strassner J, Refat M, Harris J, King B
. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017; 77(4):675-682.e1.
PMC: 6233876.
DOI: 10.1016/j.jaad.2017.05.043.
View
4.
Joshipura D, Plotnikova N, Goldminz A, Deverapalli S, Turkowski Y, Gottlieb A
. Importance of light in the treatment of vitiligo with JAK-inhibitors. J Dermatolog Treat. 2017; 29(1):98-99.
DOI: 10.1080/09546634.2017.1339013.
View
5.
Phan K, Phan S, Shumack S, Gupta M
. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis. J Dermatolog Treat. 2020; 33(1):173-177.
DOI: 10.1080/09546634.2020.1735615.
View